A retrospective clinical study on 37 subtalar arthrodesis patients of nine years follow-up

2015 ◽  
Author(s):  
Xiangyang Xu ◽  
Chonglin Yang ◽  
Yuan Zhu ◽  
Jinhao Liu ◽  
Baofu Wei
Keyword(s):  
Clinical Study ◽  
Subtalar Arthrodesis ◽  
Retrospective Clinical Study

Fixed restorations supported by Morse-taper connection implants: a retrospective clinical study with 10-20 years of follow-up

2014 ◽  
Vol 26 (10) ◽  
pp. 1229-1236 ◽  
Author(s):  
Carlo Mangano ◽  
Flavia Iaculli ◽  
Adriano Piattelli ◽  
Francesco Mangano
Keyword(s):  
Clinical Study ◽  
Retrospective Clinical Study

A comparison between enucleation of the prostate using holmium and thulium laser in volume over 80 cc: retrospective clinical study with 12-months follow-up

Urologiia ◽  
2019 ◽  
Vol 3_2019 ◽  
pp. 80-83
Author(s):  
S.V. Popov Popov ◽  
I.N. Orlov Orlov ◽  
A.G. Martov Martov ◽  
S.M. Malevich Malevich ◽  
I.V. Sushina Sushina ◽  
...  
Keyword(s):  
Clinical Study ◽  
Thulium Laser ◽  
Retrospective Clinical Study

scholarly journals The efficacy of intravitreal conbercept for chronic central serous chorioretinopathy: a retrospective clinical study

2019 ◽  
Author(s):  
Jianbo Mao ◽  
Caiyun Zhang ◽  
Chenyi Liu ◽  
Lijun Shen ◽  
Jimeng Lao ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Clinical Study ◽  
Central Serous Chorioretinopathy ◽  
Central Macular Thickness ◽  
Chronic Central Serous Chorioretinopathy ◽  
Corrected Visual Acuity ◽  
Retrospective Clinical Study ◽  
The Difference ◽  
Best Corrected Visual Acuity

Abstract Background: To evaluate the efficacy and safety of conbercept for patients with chronic central serous chorioretinopathy (CSC). Methods: A retrospective clinical study. This study included twenty-seven patients (32 eyes) who were diagnosed with chronic CSC in our hospital from November 2015 to March 2018. All the patients received intravitreal conbercept with one intravitreal injection and pro re nata (PRN). Follow-up observations occurred at 1 week and 1, 2, 3, and 6 months after initial injection. Observed indicators included best-corrected visual acuity (BCVA), central macular thickness (CMT) and presence of subretinal fluid (SRF). Results: During the 6-month follow-up, the mean number of injections required and performed was 1.50±0.67. The BCVA at the first visit, 1-week, 1-, 2-, 3- and 6-month follow-ups after the first injection was 0.44±0.26, 0.39±0.29, 0.38±0.29, 0.33±0.29, 0.31±0.30, and 0.31±0.29, respectively. The difference between the BCVA at each follow-up and the first visit was statistically significant (F=9.717, P<0.05). CMT at the first visit, 1-week, 1-, 2-, 3- and 6- month after first injection was 323.25±158.49μm, 263.78±122.52μm, 222.34±92.46μm, 195.63±69.18μm, 189.25±68.71μm, and 200.47±86.30μm, respectively. The difference between the CMT at each follow-up and the first visit was also statistically significant (F=17.072, P<0.05). Full resolution of fluid was achieved in 7 (21.9%) eyes at 1 month, 14 (43.8%) eyes at 2 months, 19 (59.4%) eyes at 3 months and 23 (71.9%) eyes at 6 months after the initial treatment of anti-VEGF injection. No severe adverse event was noted relevant to the therapy. Conclusion: Intravitreal injection of conbercept can effectively reduce the CMT and improve the BCVA in chronic CSC in a short term of 6 months. Keywords: Chronic central serous chorioretinopathy, Conbercept, Best-corrected visual acuity, Central macular thickness.

Sign in / Sign up

Export Citation Format

Share Document